Free Trial
OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Enzon Pharmaceuticals logo
$0.07 -0.01 (-12.20%)
(As of 11/20/2024 ET)

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Key Stats

Today's Range
$0.07
$0.08
50-Day Range
$0.07
$0.15
52-Week Range
$0.06
$0.24
Volume
8,584 shs
Average Volume
25,748 shs
Market Capitalization
N/A
P/E Ratio
7.21
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENZN Stock News Headlines

Enzon Pharmaceuticals Inc ENZN
OKYO Pharma Limited (OK10.F)
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Enzon Stock Hits New 52-Week Low (ENZN)
Ibnsina Pharma Co (ISPH)
See More Headlines

ENZN Stock Analysis - Frequently Asked Questions

Enzon Pharmaceuticals' stock was trading at $0.0936 at the beginning of 2024. Since then, ENZN shares have decreased by 23.1% and is now trading at $0.0720.
View the best growth stocks for 2024 here
.

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) issued its quarterly earnings data on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX).

Company Calendar

Last Earnings
4/30/2020
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
CUSIP
29390410
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$1.37 million
Pretax Margin
5,103.85%

Debt

Sales & Book Value

Annual Sales
$30,000.00

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.53

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (OTCMKTS:ENZN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners